Publications by authors named "Enrico Sciacca"
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by irreversible scarring of lung tissue, leading to death. Despite recent advancements in understanding its pathophysiology, IPF remains elusive, and therapeutic options are limited and non-curative. This review aims to synthesize the latest research developments, focusing on the molecular mechanisms driving the disease and on the related emerging treatments.
View Article and Find Full Text PDFIdiopathic pulmonary fibrosis (IPF) represents a fibrotic interstitial lung disease characterized by uncertain etiology and poor prognosis. Over the years, the path to effective treatments has been marked by a series of advances and setbacks. The introduction of approved antifibrotic drugs, pirfenidone and nintedanib, marked a pivotal moment in the management of IPF.
View Article and Find Full Text PDFArticle Synopsis
- Remdesivir is an effective treatment for patients with moderate to severe COVID-19 as it improves hypoxemic respiratory failure and reduces inflammation.
- A study involved 112 patients, comparing those treated with remdesivir plus standard care versus standard care alone, measuring changes in oxygen levels and inflammatory markers over 5 days.
- Results showed that the remdesivir group had significant improvements in oxygen levels and reduced interleukin-6 levels, leading to less need for ventilatory support and shorter hospital stays compared to the standard care group.
Objectives: To investigate relationships between histogram-based high-resolution CT (HRCT) indexes and pulmonary function tests (PFTs) in interstitial lung diseases.
Methods: Forty-nine patients having baseline and 1-year HRCT examinations and PFTs were investigated. Histogram-based HRCT indexes were calculated; strength of associations with PFTs was investigated using Pearson correlation.
Over the last three years, after the outbreak of the COVID-19 pandemic, an unprecedented number of novel diagnostic tests have been developed. Assays to evaluate the immune response to SARS-CoV-2 have been widely considered as part of the control strategy. The lateral flow immunoassay (LFIA), to detect both IgM and IgG against SARS-CoV-2, has been widely studied as a point-of-care (POC) test.
View Article and Find Full Text PDF